Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Anna Kordala (2017-2021)Anna Kordala

Project:  Identifying epigenetic modifiers of survival motor neuron protein using small molecules

Supervisors: Dr Suzan Hammond and Prof Matthew Wood

 Lab team

I began my career with a masters degree in Pharmacy (Medical University of Lodz, Poland). During my masters, I had my first experience of lab work during a placement at the University of Chicago (Department of Biochemistry and Molecular Biophysics), where I studied  mistranslation in mammalian cells. Later, I returned to Poland and worked in clinical trials management. In 2016, I moved to Oxford, initially as a Research Assistant in Prof Wood's group, and later as a DPhil student under the supervision of Dr Suzan Hammond. My current research focus is spinal muscular atrophy (SMA), which is the main genetic cause of infant mortality. Specifically, I am trying to identify epigenetic mechanisms regulating the SMN protein, the insufficiency of which leads to SMA. Having the support of the DTP has been hugely beneficial to me. I started my DPhil pregnant, so I was very grateful to be able to take 9 months off (although up to a year was possible) and also benefit from a funded maternity leave. I have also successfully applied for a supplemental funding award and used it to take part in a Randomised Controlled Trials course. That was especially valuable to me as I am planning to pursue a career in clinical trials after graduation. In the long-term I hope to continue working in the field of rare diseases such as SMA, treatments for which are now gaining momentum, with the first-ever therapies entering the market right now.

MRC logo